Axa S.A. Arrowhead Pharmaceuticals, Inc. Transaction History

Axa S.A.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$61.35 - $90.47 $1.25 Million - $1.85 Million	-20,400 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$33.21 - $51.27 $1.35 Million - $2.09 Million	-40,700 Reduced 66.61%	20,400 $878,000
Q2 2020 Aug 14, 2020	BUY	$26.12 - $43.27 $7,836 - $12,981	300 Added 0.49%	61,100 $2.64 Million
Q1 2020 May 15, 2020	SELL	$20.56 - $63.12 $378,304 - $1.16 Million	-18,400 Reduced 23.23%	60,800 $1.75 Million
Q4 2019 Feb 18, 2020	BUY	$28.14 - $73.01 $1.83 Million - $4.74 Million	64,900 Added 453.85%	79,200 $5.02 Million
Q3 2019 Nov 14, 2019	BUY	$26.26 - $34.86 $375,518 - $498,498	14,300 New	14,300 $403,000
Q2 2019 Aug 13, 2019	SELL	$17.43 - $28.82 $1.35 Million - $2.24 Million	-77,700 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$12.05 - $20.18 $275,945 - $462,122	22,900 Added 41.79%	77,700 $1.43 Million
Q4 2018 Feb 13, 2019	BUY	$10.74 - $19.7 $209,430 - $384,150	19,500 Added 55.24%	54,800 $681,000
Q3 2018 Nov 08, 2018	BUY	$14.0 - $20.3 $70,000 - $101,500	5,000 Added 16.5%	35,300 $677,000
Q2 2018 Aug 13, 2018	BUY	$6.37 - $14.02 $59,241 - $130,386	9,300 Added 44.29%	30,300 $412,000
Q4 2017 Feb 13, 2018	BUY	$3.14 - $4.5 $65,940 - $94,500	21,000	21,000 $77,000

295

92.3M

1.33M

549K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.